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By Thomas Sullivan, President, Rockpointe, Editor Policymed.com and Abraham Gitterman,  
Research Associate, Rockpointe 
O
n December 12-13, FDLI hosted the annual Enforce-
ment, Litigation & Compliance conference in Wash-
ington, DC. The two-day conference was packed with 
extremely informative topics, and included an astounding 
number of high-level government officials from the Food 
and Drug Administration (FDA), the Department of Health 
and Human Services (HHS) Office of the Inspector General 
(OIG), the Department of Justice (DOJ), and several other 
related offices. 
Below is a summary of some of the panels, quotes from par-
ticipants, and some overall analysis and commentary. It should 
be noted that all participants from the government spoke on 
their own behalf and were not speaking on behalf of their 
respective agencies. 
New Faces of Enforcement 
he irst panel of the conference included some of the top 
oicials in food and drug law and healthcare enforcement. he 
panel, moderated by Eugene M. hirolf, former Director of the 
DOJ Consumer Protection Branch, consisted of: 
•	 Michael S. Blume, Director, Consumer Protection 
Branch, U.S. Department of Justice
•	 Gregory Demske, Chief Counsel to the Inspector 
General, HHS-OIG
•	 Joseph Rannazzisi, Deputy Assistant Administrator, 
Oice of Diversion Control, U.S. Drug Enforcement 
Administration (DEA)
•	 John Roth, Director, Oice of Criminal  
Investigation, FDA 
Greg Demske spoke irst, noting that although OIG will not 
make any major changes to its enforcement priorities, there will be 
diferent approaches to the way OIG handles cases. He mentioned 
the need for change given the continuously large settlements, 
questioning whether OIG and healthcare law enforcement is doing 
enough. Demske assured the audience that OIG will continue to 
work closely with industry to engage in a productive dialogue, 
promote voluntary compliance, and to identify best practices for 
compliance and ighting healthcare fraud and waste. He noted that 
OIG will hopefully continue to engage industry like it has in the 
past year, with more industry roundtables.  
Demske did emphasize that OIG will “focus on individuals 
and the decisions they are making,” in reference to DOJ’s more 
recent focus on the Park doctrine, and OIG’s use of convictions 
under that doctrine to exclude individuals. In making this 
remark, he explained to the audience OIG’s exclusion authority, 
the diferences between mandatory and permissive exclusion, 
and discussed the Synthes and Purdue Pharma cases. Demske 
also discussed the use of corporate integrity agreements (CIAs), 
and how OIG decides whether to waive exclusion in order for 
the company or entity to enter into a CIA. In referencing the 
Purdue case, he noted how the D.C. Circuit court denied the 
executives request for a hearing en banc (all judges of the court), 
leaving executives with only the option of petitioning the Su-
preme Court for a writ of certiorari. 
Finally, Demske discussed GlaxoSmithKline’s (GSK) recent 
CIA with OIG, and the new provisions addressing the “Patient 
First Program” and the “claw back” provisions for executive 
compensation and bonuses. 
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Joseph Rannazzisi gave the next presentation, which focused 
primarily on the tremendous public health concern our coun-
try is facing regarding abuse of opioids and other pain killers. 
His animated presentation gave useful data and insight into the 
tremendous extent of this problem and the harmful efects it is 
having on our healthcare system as well as the costs. He gave an 
overview of how DEA operates and its legal authority and ju-
risdiction under the Controlled Substances Act (CSA), and the 
agency’s work with DOJ, FBI, and other federal healthcare law 
enforcement. He also discussed several cases, including one in 
which individuals were driving all the way from Massachusetts 
to Florida to get opioids. 
Next, John Roth gave a presentation on FDA’s Office of 
Criminal Investigations (OCI). He gave a broad overview 
of OCI’s mission, explained the nature of their work and 
gave some examples of recent actions and cases. OCI 
mainly deals with injunctions, seizures and criminal 
enforcement of the Food, Drug & Cosmetic Act. OCI 
works with DOJ and other law enforcement to protect 
the public health and has highly trained investigators 
that help carry out its work. OCI works closely with the 
centers at FDA (e.g. CDER, CDRH) to get information 
about where its enforcement priorities should be and 
where to investigate. 
OCI handles cases involving counterfeit pharmaceuticals 
(such as the recent Avastin case) and is also responsible for 
investigating companies that may have committed clinical trial 
fraud or made misrepresentations to FDA in their product ap-
plication or required post-market reporting. 
Finally, Michael Blume discussed DOJ’s enforcement priori-
ties and how his oice handles cases. he Consumer Protection 
Branch (CPB) is involved in all cases involving the FDCA and is 
largely involved in many of the of-label promotion cases. Blume 
noted that his oice is working in an environment of limited re-
sources, but nevertheless, uses data from various sources to help 
determine a proactive approach at pursuing cases. He said that 
CPB is reaching out more aggressively to stakeholders and con-
sumers in the industry, and is looking for cases that will change 
the behavior of industry and have a larger impact on stakehold-
ers, rather than just looking for big money settlements. 
Blume noted that his oice is being more transparent about 
the facts of each case and the unlawful conduct that occurred so 
Michael S. Blume, Director, Consumer Protection Branch, U.S. Department of Justice, engaged the audience during his 
address during the “New Faces of Enforcement” keynote. 
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the oice can send a message or 
signal to stakeholders. In other 
words, those facts and unlawful 
conduct made public are a warn-
ing for companies to know that 
they may get a knock on their 
door if similar conduct occurs 
in their business. Finally, Blume 
noted CPB’s look into requiring 
more compliance, despite OIG’s 
role. He noted that his oice is 
working with OIG and having 
a discussion about ways to hold 
companies responsible and the 
right factual circumstances to 
include enhanced penalties such 
as required compliance that 
is separate and additional to a 
CIA. Blume also noted that CPB 
is seeing more medical device 
cases involving defects or failure 
to make required reporting, and 
that this may be a growth area for the oice. 
Compliance Central with FDA Center 
Compliance Directors 
his panel included the top oicials from all of FDA’s 
Centers, including drugs, devices, biologics, foods, tobacco 
and veterinary medicine. A signiicant amount of discus-
sion from CDER focused on the new authorities under the 
Food and Drug Administration Safety and Innovation Act 
(FDASIA) regarding the drug supply chain. Douglas Stearn, 
Deputy Director for Policy and Analysis, Oice of Compliance, 
CDER, discussed the new oice in CDER that deals with drug 
supply chain issues and counterfeiting as well as a new trend 
in enforcement letters from FDA dealing with current good 
manufacturing practices (cGMP) violations. 
In response to a question about why FDA sent a cGMP 
warning letter directly to a CEO or senior level oicials, Stearn 
noted that the agency did so because quality control is a corpo-
rate commitment that FDA believes needs to be taken seriously 
by senior management. He noted how quality control is now an 
aspect of the company that is integrated, so it is important that 
someone is held accountable. 
he CDRH presentation also included a very interesting dis-
cussion of new programs the center is working on such as the 
Single Audit Program and the Case for Quality Initiative. 
Advanced Applications Panel 
his panel consisted of Jill Furman (Deputy Director, Con-
sumer Protection Branch (CPB), U.S. Department of Justice), 
Christopher B. Mead (Attorney, London & Mead) and Brien T. 
O’Connor (Partner, Ropes & Gray LLP). he panel traced some 
of the steps the government goes through in deciding whether 
to bring a case for an alleged FDCA violation. First, Ms. Fur-
man noted that a large number of cases that CPB handles come 
from qui tam relators or “whistleblowers.” Under the Qui Tam 
Mary A. Malarkey, Director, Ofice of Compliance and Biologics Quality, presented the 
notable compliance work done by CBER in 2012. 
Brien T. O’Connor, Partner, Ropes & Gray LLP, discussed 
considerations when deciding whether to negotiate a pre-
iling resolution or to contest the government’s case in a trial. 
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statute, the government must review each qui tam; however, 
the discretion and process for such review varies by oice and 
agency, thus there is not necessarily a statutory outline for what 
factors and considerations the government will look at. 
Instead, Furman noted that CPB looks at whether there have 
been any regulatory actions against the alleged company or prod-
ucts by FDA or a speciic center; whether there is a public health 
concern; whether there have been a large number of warning 
letters; and several other factors. She also noted the importance 
of a company’s initial response to an inquiry, including, where 
the response came from, the perspective of ixing the problem, 
and who was hurt. In general, she noted that the focus of CPB is 
the harm to patients/consumers caused by the product. She also 
discussed where the product its in at the company, the regulatory 
and/or enforcement history of the company, any communications 
between the agency and the company about the product, and the 
pervasiveness of the conduct or actions. 
Another important factor Furman mentioned was how 
the alleged conduct afects the regulatory approval process or 
oversight of the agency. Consequently, she noted that her oice 
decides on pursuing cases, issuing subpoenas, looking at docu-
ments, etc., when the basic fact and factors noted above show 
that a likely result will be restitution that is worth the resources 
put into it. Nevertheless, she noted that cases brought to CPB 
require a lot of resources, sometimes 2-3 agents and 2-3 lawyers, 
which can be full-time and has consequences when those gov-
ernment actors are unable to pursue other cases or work. 
here was also a brief discussion about when DOJ Criminal 
decides to get involved in FDCA violation cases. It was noted 
that DOJ Criminal, CPB, FDA, and other enforcement agencies 
work together to share information about a particular case and 
based on that work make a decision whether to pursue criminal 
charges. his raised concerns from some criminal defense at-
torneys because many companies and executives have a distrust 
about DOJ coming back ater the civil case is resolved bringing 
criminal charges. hey expressed their preference of resolving 
cases “globally,” to avoid this problem. 
Chris Mead, the attorney who represented Mark Hermelin, 
the former KV Pharmaceutical CEO who was excluded from 
federal health programs last year, discussed several aspects of 
the case and made a recommendation based on his experience. 
He said that CEOs should not be more involved in clinical and 
quality decisions then they need to be. In the case of Hermelin, 
he was heavily involved in the decision making that led to the 
company using improper machines that resulted in the creation 
of adulterated products. his involvement was the primary 
The Second Circuit decision vacated the conviction of Alfred Caronia for promoting a drug for off-label use on First Amendment 
grounds. During the “Hot Topics in Enforcement: 2012 Review, 2013 Preview”, John Fleder lead a discussion on what this 
means for the food and drug law community.
January/February 2013       UPDATE 43FDLI
FDLI Activities
conduct that led to his convictions and eventual exclusions. Be-
cause it appeared based on his role as CEO that these decisions 
were made out of greed and a total disregard for public health 
and patient safety, Mead said that other executives should take 
a hands-of approach in manufacturing and clinical decisions. 
Doing so may ensure that the company’s decisions are being 
made in an unbiased and impartial way that prioritizes public 
health and patient safety over proits. 
Hot Topics and U.S. v. Caronia 
he last panel of the irst day included a healthy discussion 
of the recent 2nd Circuit Opinion in U.S. v. Caronia. he various 
panel members discussed their viewpoints and made predic-
tions about the future of the case and its potential implications. 
Several interesting points were made. 
First, one commentator noted that for many of the compa-
nies that are involved in of-label promotion cases, the company 
usually communicated with FDA about pursuing an of-label 
indication. Consequently, the panel noted that if FDA expressly 
denies a company’s claim about another use or the company 
submits additional data about pursuing an of-label indica-
tion, with which FDA disputes, and then a company goes and 
promotes it of-label—Caronia makes it uncertain what the out-
come would be if FDA prosecuted such conduct. It was noted, 
however, that under such facts, a company may be misleading 
or making false statements about its product given FDA’s rejec-
tion or dispute regarding the of-label use. 
he panel also noted that given this opinion, the calculation and 
negotiation of damages with the government, particularly when 
false claims are involved, may be afected. For example, in calculat-
ing damages and false claims, the government typically tries to 
quantify the amount of prescriptions or the “market” for of-label 
use. In making this calculation, they may consider a certain 
percentage of doctors who were prescribing of-label without the 
efect of detailing or sales reps. Now with Caronia, as long as a sales 
rep’s speech is truthful and non-misleading, then the claims being 
submitted for them may no longer be “false.”  
FDLI
Howard R. Sklamberg, Deputy Associate Commissioner for Regulatory Affairs, ORA, FDA, outlined challenges faced by FDA in 
protecting public health while maintaining international and federal-state relations.
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